In diagnostics these days, “a lot of people are after plasma,” reports Jim Averso, vice president, sales and marketing, of I.W. Tremont.

Roche has won a nod from FDA for a new diagnostic for individual blood donation testing. The Basel-Switzerland-based company’s cobas Babesia test is for use on the cobas 6800 8800 system.

Razor Genomics has developed a test enables the identification of lung cancer patients at high risk for recurrence and allows them to be treated at a time when their cancer can still be responsive to adjuvant chemotherapy.

There’s a new entrant in the liquid biopsy space. Well, sort of. Even though OncoCell MDx was formed in 2012, it hasn’t made a great deal of noise up until this year.

Today’s molecular diagnostics testing typically involves either manual processing at a reference laboratory or automated processing by preconfigured instruments in near-patient settings, Dr. Jack Regan, CEO and founder of LexaGene, said.

A new study from the University of South Australia researchers found the number of people that die from bowel or colorectal cancer (CRC) would be much higher without pre-diagnostic colonoscopies.

Two powerhouses in pharma and medtech are working together to help people with diabetes better manage their condition. Abbott Laboratories and Sanofi will collaborate to integrate glucose sensing and insulin delivery technologies.

A Danish and Taiwanese company has won Australia’s Good Design Award for a portable diagnostic device—small enough to fit in a camera case—that allows diagnosis of infectious diseases on the spot from a single drop of blood.

10x Genomics recently priced its initial public offering of 10 million shares of its common stock at $39 per share.

Sano Genetics has partnered with GenePlaza to link individuals who have used direct-to-consumer (DTC) genetic tests with clinical trials and other research programs, the companies said recently.

Horizon Discovery Group reported recently that its total revenues as reported for the first half of 2019 rose 14 percent, thanks to large increases in revenues from its bioproduction and screening business units.

Novigenix said recently that it has tapped Belgium-based startup bioinformatics firm BioLizard to develop an artificial intelligence-based algorithm to support the transition of its Colox immuno-transcriptomic RT-PCR product onto a new platform.

Ginkgo Bioworks recently announced a $290M Series E financing round from new and prior investors.

HTG Molecular Diagnostics announced recently after the close of the market that it intends to offer an undisclosed amount of its common stock in a public offering.

OncoCyte said recently that it has entered into a definitive agreement to acquire Razor Genomics, which developed and markets a prognostic test to assess risk in early-stage lung cancer patients after surgery.